Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials
Background For patients with metastatic renal cell carcinoma (mRCC) who progress on standard-of-care therapies, there is an unmet need for novel treatments. Phase I clinical trials are designed to test the safety, toxicity and optimal dosing of novel agents. Herein, we analysed the outcomes of patie...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-12-01
|
| Series: | ESMO Open |
| Online Access: | https://esmoopen.bmj.com/content/5/6/e001073.full |